LIVIVO - Search results -

Search results

Result 1 - 9 of total 9

Search options

Article ; Online: Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence.

Zouhry, Yacine / Taibi, Abdelkader / Durand-Fontanier, Sylvaine / Darbas, Tiffany / Forestier, Geraud / Monteil, Jacques / Lebrun-Ly, Valérie / Fayemendy, Philippe / Leobon, Sophie / Jesus, Pierre / Deluche, Elise

BMC cancer

2021 Volume 21, Issue 1, Page(s) 1313

Abstract: Background: The prognostic value of a low skeletal mass index (SMI) has been investigated in locally advanced oesophageal (LAE) cancer at diagnosis. However, nothing is known about its evolution and clinical impact between initial diagnosis and ... ...

Abstract	Background: The prognostic value of a low skeletal mass index (SMI) has been investigated in locally advanced oesophageal (LAE) cancer at diagnosis. However, nothing is known about its evolution and clinical impact between initial diagnosis and recurrence. Methods: A total of 89 patients treated for LAE cancer between January 2009 and December 2019 were included in this study. Computed tomography (CT) scans before treatment and at recurrence were evaluated. SMI and other body composition parameters were analysed by the L3 scan method. Results: Participants were aged 66.0 (36.0-86) years. The incidence of low SMI increased by 12.3% between diagnosis and recurrence (70.7% vs. 83.0%, respectively) over a median follow-up of 16.9 (1.7-101.6) months. Patients with high SMI at diagnosis showed loss of muscle mass (58.0 vs. 55.2 cm Conclusions: The percentage of patients with a low SMI increased during follow-up. Our data suggest that an assessment of skeletal muscle parameters and nutrition support may be more useful in patients with a high SMI.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Body Composition ; Body Mass Index ; Esophageal Neoplasms/complications ; Esophageal Neoplasms/mortality ; Esophageal Neoplasms/physiopathology ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Muscle, Skeletal/physiopathology ; Neoplasm Recurrence, Local/complications ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/physiopathology ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Retrospective Studies ; Sarcopenia/diagnostic imaging ; Sarcopenia/etiology ; Sarcopenia/mortality ; Survival Rate ; Tomography, X-Ray Computed
Language	English
Publishing date	2021-12-07
Publishing country	England
Document type	Journal Article
ZDB-ID	2041352-X
ISSN	1471-2407 ; 1471-2407
ISSN (online)	1471-2407
ISSN	1471-2407
DOI	10.1186/s12885-021-09037-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Quality of Life of Patients With Cancer During the COVID-19 Pandemic.

Baffert, Kim-Arthur / Darbas, Tiffany / Lebrun-Ly, Valerie / Pestre-Munier, Julia / Peyramaure, Clementine / Descours, Clementine / Mondoly, Melanie / Latrouite, Simon / Bignon, Elisa / Nicouleau, Samantha / Geyl, Sophie / Leobon, Sophie / Deluche, Elise

In vivo (Athens, Greece)

2021 Volume 35, Issue 1, Page(s) 663–670

Abstract: Background: The COVID-19 pandemic has changed the organisation of medical care.: Patients and methods: This is the first prospective observational study on patient-reported outcomes, quality of life (HRQOL) and satisfaction in patients with cancer ... ...

Abstract	Background: The COVID-19 pandemic has changed the organisation of medical care. Patients and methods: This is the first prospective observational study on patient-reported outcomes, quality of life (HRQOL) and satisfaction in patients with cancer with their care management in a day hospital during the period of May-June 2020. The Generalised Anxiety Disorder Screener and 12-Item Short-Form Health Survey were used. Results: The survey was completed by 189 of 267 patients. They were generally aged 61 to 70 years and women and presented with lung, breast, or colorectal cancer. Patients had low anxiety scores (mean: 3.2±4.5), with only 11.1% showing anxiety. Risk factors of anxiety included female gender (p=0.03) and lifestyle (residence, family environment) (p=0.01). The patient's physical health was stable, whereas mental health had deteriorated (p<0.0001). Risk factors of altered HRQOL included age and lifestyle. Patients greatly appreciated all the facilities of the day hospital and its organisation. Conclusion: This study shows a preserved HRQOL and low anxiety of patients with cancer during the COVID-19 pandemic.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Anxiety/psychology ; COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19/virology ; Cross-Sectional Studies ; Female ; Health Surveys/methods ; Health Surveys/statistics & numerical data ; Humans ; Male ; Medical Oncology/methods ; Medical Oncology/statistics & numerical data ; Middle Aged ; Neoplasms/classification ; Neoplasms/psychology ; Neoplasms/therapy ; Pandemics ; Prospective Studies ; Quality of Life/psychology ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/physiology
Language	English
Publishing date	2021-01-05
Publishing country	Greece
Document type	Journal Article ; Observational Study
ZDB-ID	807031-3
ISSN	1791-7549 ; 0258-851X
ISSN (online)	1791-7549
ISSN	0258-851X
DOI	10.21873/invivo.12306
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2288: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.

The Lancet. Oncology

2022 Volume 23, Issue 8, Page(s) 1044–1054

Abstract: Background: Metastatic leiomyosarcomas have a poor prognosis, and currently doxorubicin alone is used as the standard first-line treatment. Doxorubicin combined with trabectedin has shown promising results in phase 1 and 2 studies. We aimed to identify ... ...

Abstract	Background: Metastatic leiomyosarcomas have a poor prognosis, and currently doxorubicin alone is used as the standard first-line treatment. Doxorubicin combined with trabectedin has shown promising results in phase 1 and 2 studies. We aimed to identify and compare the progression-free survival of patients with metastatic or unresectable uterine or soft tissue leiomyosarcoma treated with doxorubicin and trabectedin combined as first-line therapy versus doxorubicin alone in a phase 3 trial. Methods: LMS-04 was a randomised, multicentre, open-label, superiority phase 3 trial, which included patients from 20 centres of the French Sarcoma Group (anticancer centers or hospitals with an oncological unit) in France. Eligible patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 0-1, and had metastatic or relapsed unresectable leiomyosarcomas that had not previously been treated with chemotherapy. Patients were randomly assigned (1:1), by means of an interactive web response system (permuted blocks of different sizes from two to six), to receive either intravenous doxorubicin alone (75 mg/m Findings: Between Jan 18, 2017, and March 21, 2019, 150 patients were enrolled (67 with uterine leiomyosarcomas and 83 with soft tissue leiomyosarcomas) and included in the intention-to-treat population: 76 in the doxorubicin alone group and 74 in the doxorubicin plus trabectedin group. The median duration of follow-up was 36·9 months (IQR 30·0-43·2) in the doxorubicine group and 38·8 months (32·7-44·2) in the doxorubicin plus trabectedin group. Median progression-free survival was significantly longer with doxorubicin plus trabectedin versus doxorubicin alone (12·2 months [95% CI 10·1-15·6] vs 6·2 months [4·1-7·1]; adjusted hazard ratio 0·41 [95% CI 0·29-0·58]; p<0·0001). The most common grade 3-4 adverse events were neutropenia (ten [13%] of 75 patients in the doxorubicin alone group vs 59 [80%] in the doxorubicin plus trabectedin group), anaemia (four [5%] vs 23 [31%]), thrombocytopenia (0 vs 35 [47%]), and febrile neutropenia (seven [9%] vs 21 [28%]). Nine (12%) patients in the doxorubicin alone group and 15 (201%) patients in the doxorubicin plus trabectedin group has serious adverse events. There was only one treatment-related death, reported in the doxorubicin alone group (cardiac failure). Interpretation: Doxorubicin plus trabectedin in first-line therapy was found to significantly increase progression-free survival in patients with metastatic or unresectable leiomyosarcomas compared with doxorubicin alone, despite a higher but manageable toxicity, and could be considered an option for the first-line treatment of metastatic leiomyosarcomas. Funding: PharmaMar.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease-Free Survival ; Doxorubicin ; Female ; Humans ; Leiomyosarcoma/drug therapy ; Trabectedin
Chemical Substances	Doxorubicin (80168379AG) ; Trabectedin (ID0YZQ2TCP)
Language	English
Publishing date	2022-07-11
Publishing country	England
Document type	Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2049730-1
ISSN	1474-5488 ; 1470-2045
ISSN (online)	1474-5488
ISSN	1470-2045
DOI	10.1016/S1470-2045(22)00380-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5696: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 460: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.

Kubicek, Pierre / Cesne, Axel Le / Lervat, Cyril / Toulmonde, Maud / Chevreau, Christine / Duffaud, Florence / Le Nail, Louis-Romée / Morelle, Magali / Gaspar, Nathalie / Vérité, Cécile / Castex, Marie-Pierre / Penel, Nicolas / Saada, Esma / Causeret, Sylvain / Bertucci, François / Perrin, Christophe / Bompas, Emmanuelle / Orbach, Daniel / Laurence, Valérie /

Piperno-Neumann, Sophie / Anract, Philippe / Rios, Maria / Gentet, Jean-Claude / Mascard, Éric / Pannier, Stéphanie / Blouin, Pascale / Carrère, Sébastien / Chaigneau, Loïc / Soibinet-Oudot, Pauline / Corradini, Nadège / Boudou-Rouquette, Pascaline / Ruzic, Jean-Christophe / Lebrun-Ly, Valérie / Dubray-Longeras, Pascale / Varatharajah, Sharmini / Lebbe, Céleste / Ropars, Mickaël / Kurtz, Jean-Emmanuel / Guillemet, Cécile / Lotz, Jean-Pierre / Berchoud, Juliane / Cherrier, Grégory / Ducimetière, Françoise / Chemin, Claire / Italiano, Antoine / Honoré, Charles / Desandes, Emmanuel / Blay, Jean-Yves / Gouin, François / Marec-Bérard, Perrine

BMC cancer

2023 Volume 23, Issue 1, Page(s) 69

Abstract: Background: The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and young ...

Abstract	Background: The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and young adults (AYAs) patients with sarcoma at the national level. Patients and methods: NETSARC database gathers regularly monitored and updated data from patients with sarcoma. NETSARC was queried for patients (15-30 years) with sarcoma diagnosed from 2010 to 2017 for whom tumor resection had been performed. We reported management, locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) in AYA treated in French reference sarcoma centers (RSC) and outside RSC (non-RSC) and conducted multivariable survival analyses adjusted for classical prognostic factors. Results: Among 3,227 patients aged 15-30 years with sarcoma diagnosed between 2010 and 2017, the study included 2,227 patients with surgery data available, among whom 1,290 AYAs had been operated in RSC, and 937 AYAs in non-RSC. Significant differences in compliance to guidelines were observed including pre-treatment biopsy (RSC: 85.9%; non-RSC 48.1%), pre-treatment imaging (RSC: 86.8%; non-RSC: 56.5%) and R0 margins (RSC 57.6%; non-RSC: 20.2%) (p < 0.001). 3y-OS rates were 81.1% (95%CI 78.3-83.6) in AYA in RSC and 82.7% (95%CI 79.4-85.5) in AYA in non-RSC, respectively. Whereas no significant differences in OS was observed in AYAs treated in RSC and in non-RSC, LRFS and PFS were improved in AYAs treated in RSC compared to AYAs treated in non-RSC (Hazard Ratios (HR): 0.58 and 0.83, respectively). Conclusions: This study highlights the importance for AYA patients with sarcoma to be managed in national sarcoma reference centers involving multidisciplinary medical teams with paediatric and adult oncologists.
MeSH term(s)	Humans ; Adolescent ; Young Adult ; Child ; Prospective Studies ; Sarcoma/diagnosis ; Sarcoma/surgery ; Soft Tissue Neoplasms/surgery ; Databases, Factual ; Progression-Free Survival
Language	English
Publishing date	2023-01-20
Publishing country	England
Document type	Journal Article
ZDB-ID	2041352-X
ISSN	1471-2407 ; 1471-2407
ISSN (online)	1471-2407
ISSN	1471-2407
DOI	10.1186/s12885-023-10556-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients' Profiles With Oxaliplatin-Induced Peripheral Neuropathy.

Kerckhove, Nicolas / Selvy, Marie / Lambert, Céline / Gonneau, Coralie / Feydel, Gabrielle / Pétorin, Caroline / Vimal-Baguet, Agnès / Melnikov, Sergey / Kullab, Sharif / Hebbar, Mohamed / Bouché, Olivier / Slimano, Florian / Bourgeois, Vincent / Lebrun-Ly, Valérie / Thuillier, Frédéric / Mazard, Thibault / Tavan, David / Benmammar, Kheir Eddine / Monange, Brigitte /

Ramdani, Mohamed / Péré-Vergé, Denis / Huet-Penz, Floriane / Bedjaoui, Ahmed / Genty, Florent / Leyronnas, Cécile / Busserolles, Jérôme / Trévis, Sophie / Pinon, Vincent / Pezet, Denis / Balayssac, David

Frontiers in pharmacology

2021 Volume 12, Page(s) 744085

Abstract: Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in ... ...

Abstract	Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was designed to explore the possibility that different clusters of patients may co-exist among a cohort of patients with oxaliplatin-related CIPN. Other objectives were to characterize these clusters considering CIPN severity, anxiety, depression, health-related quality of life (HRQOL), patients' characteristics and oxaliplatin treatments. Among the 96 patients analyzed, three clusters were identified (cluster 1: 52, cluster 2: 34, and cluster 3: 10 patients). Clusters were significantly different according to CIPN severity and the proportion of neuropathic pain (cluster 1: low, cluster 2: intermediate, and cluster 3: high). Anxiety, depressive disorders and HRQOL alteration were lower in cluster 1 in comparison to clusters 2 and 3, but not different between clusters 2 and 3. This study underlines that patients with CIPN are not a homogenous group, and that CIPN severity is associated with psychological distress and a decline of HRQOL. Further studies are needed to explore the relation between clusters and CIPN management.
Language	English
Publishing date	2021-11-04
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2021.744085
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.

International journal of oncology

2019 Volume 54, Issue 4, Page(s) 1433–1445

Abstract: Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study, we evaluated the effects of aflibercept in first‑line therapy with ... ...

Abstract	Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study, we evaluated the effects of aflibercept in first‑line therapy with FOLFOX followed by maintenance with fluoropyrimidine. VELVET was a prospective, single‑arm multicenter phase II study (completed). Patients with previously untreated, unresectable, evaluable or measurable mCRC, with an age ≥18 years, and an ECOG performance status of 0‑2 received 6 cycles of modified FOLFOX7 (5‑FU/folinic acid and oxaliplatin) with aflibercept at 4 mg/kg every 2 weeks followed by maintenance therapy with fluoropyrimidine with aflibercept until disease progression or limiting toxicity. The reintroduction of oxaliplatin was performed at first progression. The primary endpoint was progression‑free survival (PFS) at 6 months. From May, 2013 to May, 2014, 49 patients were included and 48 were evaluable for response. In total, 33 patients (67.4%) were alive without progression at 6 months. The Kaplan‑Meier survival 6‑month and 1‑year PFS rates were 79.1 and 36.1%, respectively, and the median PFS was 9.3 months (95% CI, 8.3‑12.5). The objective response rate was 59.2% (N=29/49). The most common (≥10%) grade 3‑4 adverse events were hypertension (23%), fatigue (15%), neutropenia (12%), neuropathy (12%) and stomatitis (10%). Three (6%) treatment‑related deaths occurred: One from stroke, one from pulmonary embolism and one from neutropenic sepsis. On the whole, this study demonstrates the efficacy of aflibercept in combination with an oxaliplatin‑based regimen in the first‑line therapy of patients with mCRC. A strict monitoring of blood pressure and immediate management of hypertension during therapy is mandatory.
MeSH term(s)	Administration, Intravenous ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Drug Administration Schedule ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Maintenance Chemotherapy ; Male ; Middle Aged ; Neoplasm Metastasis ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Prospective Studies ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/adverse effects ; Survival Analysis ; Treatment Outcome
Chemical Substances	Organoplatinum Compounds ; Recombinant Fusion Proteins ; aflibercept (15C2VL427D) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2019-02-01
Publishing country	Greece
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study
ZDB-ID	1154403-x
ISSN	1791-2423 ; 1019-6439
ISSN (online)	1791-2423
ISSN	1019-6439
DOI	10.3892/ijo.2019.4709
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3690: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study.

Selvy, Marie / Pereira, Bruno / Kerckhove, Nicolas / Gonneau, Coralie / Feydel, Gabrielle / Pétorin, Caroline / Vimal-Baguet, Agnès / Melnikov, Sergey / Kullab, Sharif / Hebbar, Mohamed / Bouché, Olivier / Slimano, Florian / Bourgeois, Vincent / Lebrun-Ly, Valérie / Thuillier, Frédéric / Mazard, Thibault / Tavan, David / Benmammar, Kheir Eddine / Monange, Brigitte /

Ramdani, Mohamed / Péré-Vergé, Denis / Huet-Penz, Floriane / Bedjaoui, Ahmed / Genty, Florent / Leyronnas, Cécile / Busserolles, Jérôme / Trevis, Sophie / Pinon, Vincent / Pezet, Denis / Balayssac, David

Journal of clinical medicine

2020 Volume 9, Issue 8

Abstract: 1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer ... ...

Abstract	(1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal cancer. (2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess the prevalence of CIPN, as well as its consequences (neuropathic pain, anxiety, depression, and quality of life) in cancer survivors during the 5 years after the end of adjuvant oxaliplatin chemotherapy. (3) Results: Out of 406 patients, the prevalence of CIPN was 31.3% (95% confidence interval: 26.8-36.0). Little improvement in CIPN was found over the 5 years, and 36.5% of patients with CIPN also had neuropathic pain. CIPN was associated with anxiety, depression, and deterioration of quality of life. None of the patients with CIPN were treated with duloxetine (recommendation from American Society of Clinical Oncology), and only 3.2%, 1.6%, and 1.6% were treated with pregabalin, gabapentin, and amitriptyline, respectively. (4) Conclusions: Five years after the end of chemotherapy, a quarter of patients suffered from CIPN. The present study showed marked psychological distress and uncovered a failure in management in these patients.
Language	English
Publishing date	2020-07-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm9082400
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.

Vénat-Bouvet, Laurence / Saint-Marcoux, Franck / Lagarde, Christian / Peyronnet, Pierre / Lebrun-Ly, Valérie / Tubiana-Mathieu, Nicole

Anti-cancer drugs

2007 Volume 18, Issue 8, Page(s) 977–980

Abstract: The pharmacokinetics of irinotecan and its metabolites has been widely studied. No pharmacokinetic data, however, are available in haemodialysis patients. We report two clinical cases of severe toxicity, one of which was fatal, in two haemodialysis ... ...

Abstract	The pharmacokinetics of irinotecan and its metabolites has been widely studied. No pharmacokinetic data, however, are available in haemodialysis patients. We report two clinical cases of severe toxicity, one of which was fatal, in two haemodialysis patients treated with irinotecan for a metastatic colorectal cancer. In case no. 1, M.S., aged 71 years, was treated with first-line FOLFIRI chemotherapy (irinotecan 180 mg/m) for local recurrence with liver metastases of a colon cancer treated with an LV5FU2 protocol as an adjuvant therapy 3 years previously. After the first cycle of irinotecan, the patient presented grade 4 diarrhoea on day 9, then a febrile grade 4 neutropenia on day 14 leading to his death on day 18. In case no. 2, M.D., aged 57 years, was treated successively by radiochemotherapy with an LV5FU2 regimen, then with four cycles of FOLFIRI (irinotecan at 125 mg/m) and finally with the cetuximab/irinotecan combination using the conventional dosage. Febrile neutropenia was observed on day 10 of the first irinotecan infusion with a dose of 180 mg/m and on day 8 of the second infusion with a lower dose of 120 mg/m. The patient's general condition progressively deteriorated with the advancement of the neoplastic disease, which led ultimately to his death. In this patient, plasma concentrations of irinotecan and its metabolite, SN-38, were measured during the course of the first FOLFIRI cycle on day 2 and on day 4, before and after dialysis sessions. The observed results suggest that, although irinotecan is partially dialysable, SN-38 is not. In conclusion, dose recommendations have to be defined in haemodialysis patients with renal dysfunction owing to the potential toxicity of irinotecan in these patients. Special care should be taken in liver metastasis cases owing to the nondialysability of SN-38.
MeSH term(s)	Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Agents, Phytogenic/administration & dosage ; Antineoplastic Agents, Phytogenic/pharmacokinetics ; Antineoplastic Agents, Phytogenic/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Camptothecin/pharmacokinetics ; Camptothecin/therapeutic use ; Colorectal Neoplasms/complications ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Combined Modality Therapy ; Diarrhea/complications ; Fluorouracil/administration & dosage ; Granulomatosis with Polyangiitis/complications ; Hemorrhage/complications ; Humans ; Kidney Failure, Chronic/complications ; Kidney Failure, Chronic/therapy ; Male ; Middle Aged ; Renal Dialysis
Chemical Substances	Antimetabolites, Antineoplastic ; Antineoplastic Agents, Phytogenic ; irinotecan (7673326042) ; Fluorouracil (U3P01618RT) ; Camptothecin (XT3Z54Z28A)
Language	English
Publishing date	2007-09
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	1065301-6
ISSN	1473-5741 ; 0959-4973
ISSN (online)	1473-5741
ISSN	0959-4973
DOI	10.1097/CAD.0b013e32811d69cb
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3125: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy.

Sparsa, Agnès / Lesaux, Nicolas / Kessler, Emmanuel / Bonnetblanc, Jean-Marie / Blaise, Sophie / Lebrun-Ly, Valérie / Colombeau, Pierre / Vidal, Elisabeth / Bédane, Christophe

Journal of the American Academy of Dermatology

2005 Volume 53, Issue 5 Suppl 1, Page(s) S263–5

Abstract: We describe the unusual case of a 78-year-old woman consulting for extensive and painful wound leg ulcerations and calcifications secondary to CREST syndrome that was treated by extracorporeal shock wave lithotripsy. This treatment was considered because ...

Abstract	We describe the unusual case of a 78-year-old woman consulting for extensive and painful wound leg ulcerations and calcifications secondary to CREST syndrome that was treated by extracorporeal shock wave lithotripsy. This treatment was considered because of the severity of our patient's symptoms and her failure to respond to various medical and surgical treatment.
MeSH term(s)	Aged ; CREST Syndrome/therapy ; Calcinosis/epidemiology ; Calcinosis/therapy ; Comorbidity ; Female ; Humans ; Leg Ulcer/epidemiology ; Leg Ulcer/therapy ; Lithotripsy ; Skin Diseases/epidemiology ; Skin Diseases/therapy
Language	English
Publishing date	2005-11
Publishing country	United States
Document type	Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	603641-7
ISSN	1097-6787 ; 0190-9622
ISSN (online)	1097-6787
ISSN	0190-9622
DOI	10.1016/j.jaad.2005.04.010
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1540: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito